Cost-effectiveness of stockpiling 23-valent pneumococcal polysaccharide vaccine to prevent secondary pneumococcal infections among a high-risk population in the united states during an influenza pandemic

Dhankhar P, Grabenstein JD, O'Brien MA, Dasbach EJ

Record Status
This is an economic evaluation that meets the criteria for inclusion on NHS EED.

Bibliographic details

DOI
10.1016/j.clinthera.2010.07.019

Indexing Status
Subject indexing assigned by NLM

MeSH
Adolescent; Adult; Cost of Illness; Cost-Benefit Analysis; Humans; Influenza, Human /complications /epidemiology; Middle Aged; Models, Economic; Pandemics; Pneumococcal Infections /economics /etiology /prevention & control; Pneumococcal Vaccines /administration & dosage /economics /supply & distribution; Quality-Adjusted Life Years; Risk Factors; United States /epidemiology

AccessionNumber
22010001597

Date bibliographic record published
02/02/2011